Dear Colleagues and Guests

The field of preclinical and clinical lymphoma research has seen a dramatic acceleration of progress during the last years, ranging from a molecular characterization of the disease to the development of novel mouse models, as well as preclinical drug development, ultimately culminating in massive advances in our current treatment algorithms, now involving CAR-T cells, various novel (bispecific) antibodies and new small molecule compounds.

In parallel to these scientific developments, within the state of Northrhine-Westphalia, the large comprehensive cancer centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have strategically strengthened their collaboration, particularly through the establishment of the National Cancer Center West NCT-West (Essen, Cologne), and have further consolidated and expanded their clinical and translational lymphoma programs.

Given these developments, we are excited to launch the bi-annual West German Lymphoma Symposium, to facilitate the scientific exchange within the region, excite young researchers for lymphoma research, and, most importantly, to further expand our international visibility and outreach.

The organizing team of the West German Lymphoma Symposium is happy to invite you to be part of our inaugural meeting. The meeting will take place on 24th and 25th of May 2024 in Essen, Germany at the heart of the Ruhrgebiet.

We would be absolutely thrilled if you could join us for this event. You are cordially invited to submit an Abstract. There will be short talks selected from the best abstracts, as well as poster awards.

With all our best wishes and warm regards Conference chair


Christian Reinhardt, Prof. Dr Bastian v. Tresckow, Prof. Dr Ralf Küppers, Prof. Dr University Hospital Essen, West German Cancer Center

Peter Borchmann, Prof. Dr University Hospital Cologne, Clinic for Internal Medicine Oncology/ Haematology

Sascha Dietrich, Prof. Dr University Hospital Düsseldorf Clinic for Haematology, Oncology and Clinical Immunology

Under the auspices of

Scientific lead and response for the programme



Department of Haematology and Stem Cell Transplantation West German Cancer Center University Hospital Essen (AöR) Hufelandstraße 55, 45147 Essen (Germany)

Meeting Office / Organizer and Contact CSi Hamburg GmbH Goernestraße 30, 20249 Hamburg (Germany) +49 40 30770300 meetings@csihamburg.de

Venue

Conference Center Essen Huyssenallee 55 45128 Essen (Germany) Nordrhein-Westfalen (NRW)



Hybrid Event

In co-operation with





Unter der Schirmherrschaft de

Start your registration https://www.lymphoma-symposium.de



• DÜSSELDORF • COLOGNE

ESSEN

CLINIC MEETS BIOLOGY

WEST GERMAN LYMPHOMA SYMPOSIUM

www.lymphoma-symposium.de

24th and 25th May 2024

Conference Center Essen (Germany)

PRELIMINARY PROGRAMME

DAY 1	FRIDAY, 24 th MAY 2024	DAY 2
from 09:30	Registration	8:00-10:0
10:45	Welcome	
10.45	Scientific committee	Charte
		Chair
11:00-1:00	Session 1	8:00
	The germinal center reaction as a catalyst	
	for lymphoma development	
Chair	Christian Reinhardt, University Hospital Essen (GER)	8:25
11:00	Role of Super-enhancer Hypermutation in the	
	Pathogenesis of Diffuse Large B cell Lymphoma	8:50
	Riccardo Dalla-Favera, Columbia University New York (USA)	
11:25	Genetics-driven epigenetic disruption of the	9:15
	germinal center program in B cell lymphomas	
	Laura Pasqualucci, Columbia University New York (USA)	9:40
11:50	Aspects of Hodgkin lymphoma biology	
	Ralf Küppers, University Hospital Essen (GER)	
12:15	Modelling Sporadic Oncogenic Events	
	in Lympho magenesis	0.50
42.40	Dinis Calado, The Francis Crick Institute London (UK)	9:50
12:40	Short talk I - "Unveiling Follicular Lymphoma's	
	Common Progenitor Cells"	10:00-10:
12:50	Oscar Atkins, The Francis Crick Institute (UK) Discussion	10.20 12.
12.50	Discussion	10:30-12:
1:00-2:00	Break	
2:00-4:00	Session 2	Chair
	Epigenetic rewiring as a driver	10:30
	and target of lymphomagenesis	
Chair	Peter Borchmann, University Hospital Cologne (GER)	
2:00	Mechanisms and therapeutic targeting	10:55
	of the malignant immune system	
	Ari M. Melnick, Weill Cornell Medicine New York (USA)	
2:25	Development of small molecules	11:20
	for epigenetic targets	
	Stefan Knapp, Goethe-University Frankfurt (GER)	
2:50	Harnessing state switches	
	in aggressive B-cell lymphoma	
	Clemens Schmitt, Charité - University Hospital Berlin (GER)	11:45
3:15	DNA-methylation based classification	
	of lymphomas: A tool to come?	
3:40	Reiner Siebert, Ulm University Hospital (GER) Toward the noninvasive characterization	
3:40 REMOTE	of lymphomas & their microenvironments	12:10
RENOTE	Ash A. Alizadeh, Stanford University / Stanford	
	Comprehensive Cancer Center (USA)	
4:00-6:00	Poster presentation and Get-together	12:35
	Ster presentation and det together	12.35

.

	SATURDAY, 25 th MAY 2024
00	Session 3 Genetic rewiring encodes actionable vulnerabilities in lymphoma Sascha Dietrich, University Hospital Düsseldorf (GER)
	Genetic bases of immune evasion in lymphoma Margaret Shipp, Dana Farber/Harvard Cancer Center Boston (USA)
	Curing aggressive lymphomas with aggressive combinations of targeted agents Louis Staudt, National Cancer Institute Bethesda (USA) Actionable Alterations in LBCL
	Björn Chapuy, Charité University Medicine Berlin (GER) Elucidation of Lymphoma Proteogenotypes Thomas Oellerich, University Hospital Frankfurt (GER) Short talk II - "Autonomous B-cell receptor
	signaling in activated B-cell DLBCL:
	A lymphomagenic driver with functional equivalence to an activating CARD11 variant Hendrik Veelken, Leiden University Medical Center (NL) Discussion
0:30	Break
2:45	Session 4 The next frontier: harnessing the immune system for lymphoma therapy Bastian von Tresckow, University Hospital Essen (GER)
	Chemotherapy free approaches in first line LBCL - a dream or a reality? Jason Westin, University of Texas MD Anderson Cancer Center Houston (USA) Enhancing immunotherapies for germinal center- derived B cell lymphomas by EZH2 inhibition Wendy Béguelin, Weill Cornell Medicine New York, (USA) Multi-omic profiling of CAR T cell treated
	aggressive B-cell lymphoma reveals a CSF1R+ myeloid-monocytic cell compartment mediating CAR T cell resistance Roland Ullrich, University Hospital Cologne (GER) Bispecific T Cell Engagers in Follicular Lymphoma:
	Promises and Path Ahead Elisabeth Budde, City of Hope National Medical Center Duarte (USA) Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities Sascha Dietrich, University Hospital Düsseldorf (GER) Discussion

12:45-1:45	Break
1:45-3:30	Session 5
	Mechanisms of resistance and
	definition of high-risk DLBCL
Chair	Ralf Küppers, University Hospital Essen (GER)
1:45	Short talk III - "Targeting N-linked
	Glycosylation for the Therapy of Aggressive
	Lymphomas"
	S. Scheich, University Hospital Frankfurt, Frankfurt (GER)
1:55	Mechanisms of resistance and
	definition of high-risk DLBCL
	Andrew Davies, Southampton General Hospital (UK)
2:20	Overcoming therapy resistance
	through single-cell functional precision
	medicine approaches
	Philipp Staber, Medical University of Vienna (AUT)
2:45	Autochthonous mouse models of DLBCL
	enable in vivo genetic screening and
	serve as a platorm for preclinical validation
	of actionable vulnerabilities
	Christian Reinhardt, University Hospital Essen (GER)
3:10	Discussion
3:30	Closing remarks
	Farewell and Goodbye
	Status May 2024. Subject to change
SPONSORS - T	hank you for the support
	rie <i>Liee</i> , (Roche)
000	rie Lilly (Roche)

ر^{اا} Bristol Myers Squibb™

.

•

•

Incyte

In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA

Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services. Net amounts, before deduction of costs. AbbVie Deutschland GmbH & Co. KG, 50,000 € - BeiGene, 5.000 € - Bristol-Myers Squibb GmbH & Co. KGaA, 20,000 € - Incyte Inc., 10,000 € - Janssen-Cilag GmbH, 5.000 € - Lilly Deutschland GmbH, 50,000 € - MSD Sharp & Dohme GmbH, 5.000 € - Roche Pharma AG, 50.000 € - sobi GmbH, 5.000 € - Takeda Pharma Vertrieb GmbH & Co. KG, 5,000 € -Status: 05/2024